Resmetirom Effects Consistent Across MASH Genotypes
A phase 3 trial found resmetirom's impact on MASH, fibrosis, and liver fat does not vary significantly by common genotypes linked to more severe disease.
This matters for patients with MASH and their care providers, based on findings from a randomised trial.
- study
- resmetirom's effects on MASH, fibrosis, and liver fat
Taken from the source as published — check the details before acting on them.
Study design and population
The analysis was based on data from a phase 3 trial involving participants with MASH and varying genotypes associated with disease severity.
Key findings
The drug's effects on liver fat, fibrosis, and MASH were consistent across different genotypes, according to the researchers.
Common questions
Does resmetirom work the same for all MASH patients?
The trial suggests resmetirom's effects on liver fat, fibrosis, and MASH are consistent across common genotypes linked to more severe disease.
What type of study was this?
The findings come from a phase 3 trial, which is a randomised study involving a large group of participants.
Sources
- Resmetirom Benefit Similar Across MASH Risk Genotypes Medscape · medscape.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
